Liver injury in mild COVID-19 with various COVID pandemic phases, a real-world study.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

TCTR

Registry ID

TCTR20230320008

Enrollment

300

Registered

2023-03-20

Start date

2021-09-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

To evaluate in the proportion of patients with COVID-19 infection and hospitalized in the hospital, hospital field, and cohort ward with liver injury due to a variety of real-world anti-COVID-19 medications and other consequences of COVID-19 infection. COVID-19, liver injury, Andrographis paniculata, Favipiravir, Ivermectin, Remdesivir, and Monulpiravir.

Interventions

For patients with COVID-19 who admitted at hospitel and hospital fields, symptomatic COVID-19 without pneumonia, and absence of risk factors for severe disease.,For patients with COVID-19 who admitted

Other,Other

Hospitel and hospital fields,Cohort ward

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Eligible individuals were inpatients age >18 years, who were admitted to the hospitel, hospital field, and cohort ward after RT-PCR testing confirmed the diagnosis of COVID-19 infection. For hospitel and hospital fields, symptomatic COVID-19 without pneumonia, and absence of risk factors for severe disease are inclusion criteria. Any of the following cohort wards qualify for symptomatic COVID-19 treatment: having severe illness risk factors or with mild pneumonia.

Exclusion criteria

Exclusion criteria: 1.Patients with pneumonia and hypoxia will require an oxygen supplement 2.Patients with moderate to severe pneumonia (infiltration > 20% of total lung) 3.Pregnant or breast- feeding women.

Design outcomes

Primary

Measure	Time frame
Liver injury 10 days The severity of liver injury was classified as mild (below 2 times), moderate (2-5 times), and severe (over 5 times) based on AST and/or ALT levels that were larger than UNL.	—

Secondary

Measure	Time frame
Associated with liver injury 10 days Baseline demographic information, pre-existing liver disease, medication during hospitalization, etc.	—

Countries

Thailand

Contacts

Public ContactJirayuth Winyupakorn

Faculty of medicine , Navamintharadhiraj university

jirayuth@nmu.ac.th0917628699

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026